9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

Local anaesthetics reversibly interrupt neural conduction along peripheral and central axonal pathways by inhibiting voltage-gated sodium channels. Their therapeutic efficacy, duration of sensory and motor blockade, and potential for catastrophic systemic toxicity are directly dictated by their molecular architecture, physicochemical properties, and intracellular binding dynamics.

---

1. Chemical Architecture and Classification

All clinically utilized local anaesthetics share a common tripartite molecular framework:

   [ LIPOPHILIC AROMATIC RING ] ------ [ INTERMEDIATE CHAIN ] ------ [ HYDROPHILIC AMINE ]
          (Benzene Ring)                    (Ester or Amide)              (Tertiary Amine)
                 |                                 |                             |
         Confers Lipid                     Determines Pathway             Accepts Proton;
         Solubility & Potency              of Elimination & Allergy       Exists as Base (B) or Cation (BH+)

1. Lipophilic Aromatic Group: Typically a substituted benzene ring that facilitates diffusion across hydrophobic lipoprotein neural membranes.
2. Intermediate Chain: A hydrocarbon chain linking the aromatic head to the amine tail via either an ester ($-COO-$) or an amide ($-NHCO-$) bond.
3. Hydrophilic Amine Group: Usually a tertiary or secondary amine that acts as a weak base, accepting a hydrogen ion ($H^+$) to become a charged cation.

The "I" Mnemonic and Metabolic Pathways

• Amides ("Two I's"): Lidocaine, bupivacaine, ropivacaine, prilocaine, levobupivacaine, and articaine (articaine contains both an amide linkage and an ancillary ester group on its thiophene ring).
  • Metabolism: Amides undergo extensive hepatic microsomal degradation by cytochrome P450 enzymes (predominantly CYP1A2 and CYP3A4), involving dealkylation and hydroxylation. Elimination half-lives are relatively long (lidocaine $1.5 - 2\text{ hours}$, bupivacaine $3.5\text{ hours}$). Clearance is directly dependent on hepatic blood flow and intrinsic enzyme function. True IgE-mediated allergic reactions to amides are vanishingly rare ($<1\%$ of all adverse events); when hypersensitivity occurs, it is almost universally triggered by the preservative methylparaben (structurally similar to PABA) or sodium metabisulfite added to multi-dose vials.
• Esters ("One I"): Procaine, tetracaine, chloroprocaine, cocaine, and benzocaine (the only "i" is in the shared "-caine" suffix).
  • Metabolism: Esters are rapidly hydrolyzed in the bloodstream and tissues by circulating plasma butyrylcholinesterase (pseudocholinesterase). Elimination half-lives are exceptionally short (chloroprocaine $<1\text{ minute}$). Ester hydrolysis generates para-aminobenzoic acid (PABA) and its derivatives, which act as potent haptens capable of sensitizing lymphocytes and triggering true IgE-mediated anaphylaxis. Patients with congenital pseudocholinesterase deficiency (atypical enzyme) exhibit prolonged clearance and heightened toxicity risks from ester local anaesthetics.

---

2. Mechanism of Action and the Modulated Receptor Hypothesis

Local anaesthetics interrupt the generation and propagation of action potentials along excitable neural membranes by binding to the pore-forming alpha-subunit of voltage-gated sodium channels ($Na_V1.1$ to $Na_V1.9$).

                          [ AXONAL MEMBRANE PERMEATION ]

      EXTRACELLULAR SPACE (pH 7.4)                   INTRACELLULAR AXOPLASM (pH 7.2)
      ============================                   ===============================
               BH+ (85%)                                      BH+ (Active Cation)
                ^                                              ^
                |                                              |
         (H+) + B   (15%)   ----------> [ DIFFUSION ] ------>  B   + (H+)
               [Uncharged]              Through Lipid         [Uncharged]
                                        Bilayer
                                                               |
                                                               v
                                                     [ Binds to S6 Domain IV ]
                                                     Inside NaV Channel Pore
                                                     From the Cytoplasmic Face
                                                               |
                                                               v
                                                     Blocks Na+ Influx -> Apnea of Conduction

The Dual-Form Equilibrium

Local anaesthetics exist in an aqueous equilibrium between an uncharged, non-ionized lipophilic free base ($\text{B}$) and a positively charged, ionized hydrophilic cation ($\text{BH}^+$): $\text{B} + \text{H}^+ \xrightleftharpoons{} \text{BH}^+$

• Membrane Penetration: The lipid bilayer of the perineurium and axonal membrane represents an impermeable barrier to charged ions. Only the uncharged lipophilic base ($\text{B}$) can cross the axonal membrane into the cytoplasm.
• Channel Blockade: Once inside the axoplasm (pH ~7.2), the molecule re-equilibrates. The charged cation ($\text{BH}^+$) binds with high affinity to a specific receptor binding site located within the inner vestibule of the sodium channel pore (specifically residues on the S6 transmembrane segment of domain IV). Positively charged $\text{BH}^+$ sterically occludes the pore and electrostatically repels incoming sodium ions, preventing the regenerative depolarizing Phase 0 inward sodium current.

The Modulated Receptor Hypothesis (Hille)

Voltage-gated sodium channels cycle through three distinct functional conformations:

1. Resting (Closed): The activation gate is closed; the inactivation gate is open.
2. Open (Activated): Membrane depolarization triggers rapid opening of the activation gate; $Na^+$ ions rush into the cell.
3. Inactivated (Refractory): Within 1 millisecond, the intracellular inactivation loop (the IFM motif: isoleucine-phenylalanine-methionine) swings into the inner pore, plugging the channel.

Local anaesthetic molecules possess dramatically higher binding affinity for the open and inactivated states than for the resting state. As a result, repetitive, high-frequency neural firing drives channels into the high-affinity open/inactivated configurations, accelerating and intensifying the block—a phenomenon designated use-dependent (or frequency-dependent) blockade. Nerves that fire at high frequencies (such as sensory pain C-fibers and $A\delta$-fibers) are blocked far more rapidly than infrequently firing motor fibers.

Differential Nerve Block Sensitivity

Susceptibility of peripheral nerve fibers to local anaesthetic blockade depends on fiber diameter, myelination, and conduction velocity:

• $B$-Fibers: Small diameter ($<3\text{ }\mu\text{m}$), lightly myelinated preganglionic autonomic fibers; the most sensitive to blockade. Sympathetic blockade typically extends 2 to 4 dermatomes higher than sensory blockade during neuraxial anaesthesia.
• $A\delta$ and $C$ Fibers: Small diameter, transmitting dull/sharp pain and temperature; blocked early.
• $A\beta$ and $A\gamma$ Fibers: Intermediate diameter, transmitting touch, pressure, and muscle spindle afferents; intermediate sensitivity.
• $A\alpha$ Fibers: Large diameter ($12 - 20\text{ }\mu\text{m}$), heavily myelinated somatic motor and proprioceptive fibers; the most resistant to blockade (requiring highest drug concentrations).

---

3. Physicochemical Determinants of Clinical Performance

Physicochemical Profiles of Common Local Anaesthetics

The Chloroprocaine Paradox

Under strict Henderson-Hasselbalch kinetics, chloroprocaine ($pK_a = 8.7$) has only ~5% of its molecules in the uncharged base form at pH 7.4, which theoretically should produce a sluggish onset. However, in clinical practice, chloroprocaine has the fastest onset of all local anaesthetics. Because chloroprocaine is rapidly degraded by pseudocholinesterase in plasma, its systemic toxicity profile is exceptionally benign, allowing it to be safely formulated and administered at a massive concentration (2% to 3% = 20 to 30 mg/mL; compared to bupivacaine at 0.25% to 0.5% = 2.5 to 5 mg/mL). The sheer concentration gradient drives a vast absolute number of uncharged base molecules across the axonal membrane per unit time, overwhelming the low percentage fraction.

The Acidotic Tissue Trap

In infected or inflamed tissue, the extracellular microenvironment is acidic (pH drops to $5.5 - 6.2$). Under these conditions, the Henderson-Hasselbalch equilibrium shifts massively to the left: $\text{pH} - pK_a = \log_{10}\left(\frac{[\text{B}]}{[\text{BH}^+]}\right)$ Virtually 99.9% of the local anaesthetic is trapped in the charged, impermeable cationic form ($\text{BH}^+$). Because almost no uncharged base ($\text{B}$) exists to permeate the nerve sheath, local anaesthesia fails completely when injected directly into infected or phlegmonous tissues.

---

4. Local Anaesthetic Additives and Special Toxicities

Additives

• Epinephrine ($1:200{,}000$ or $5\text{ mcg/mL}$): Induces local $\alpha_1$-mediated arteriolar vasoconstriction, which slows systemic vascular absorption, decreases peak arterial plasma drug concentration ($C_{\max}$), and prolongs the duration of neural blockade by up to 50% for intermediate-acting agents (lidocaine). In addition, it serves as an immediate marker of accidental intravascular injection (producing an instantaneous heart rate increase $>10\text{ bpm}$ or systolic blood pressure rise $>15\text{ mmHg}$). Epinephrine is relatively contraindicated in regions with compromised terminal end-arterial perfusion (digits, penis, tip of nose).
• Sodium Bicarbonate ($8.4\%$): Adding 1 mL of $8.4\%$ $\text{NaHCO}_3$ to 10 mL of 1% or 2% lidocaine raises the pH of the commercial solution (which is acidic, especially epinephrine-containing preparations, to prolong shelf-life). Alkalinization substantially increases the percentage of uncharged base, dramatically accelerating the onset of neural blockade and reducing the stinging sensation upon subcutaneous infiltration.
• Perineural Adjuvants: Dexamethasone ($2 - 4\text{ mg}$ preservative-free), clonidine ($0.5 - 1.0\text{ mcg/kg}$), and dexmedetomidine ($0.5 - 1.0\text{ mcg/kg}$) prolong sensory block duration by suppressing nociceptive C-fiber discharge and mediating local vasoconstriction.

Prilocaine and Methemoglobinemia

Prilocaine undergoes hepatic metabolism by cytochrome P450 enzymes to produce the aromatic metabolite $o$-toluidine (ortho-toluidine). $o$-Toluidine is an oxidant that oxidizes the ferrous iron ($Fe^{2+}$) of normal hemoglobin to the ferric iron ($Fe^{3+}$) state, forming methemoglobin ($MetHb$): $\text{Hemoglobin-Fe}^{2+} \xrightarrow{o\text{-Toluidine}} \text{Methemoglobin-Fe}^{3+}$

• Consequences: Ferric iron ($Fe^{3+}$) cannot bind oxygen. Furthermore, its presence distorts the remaining ferrous heme groups within the hemoglobin tetramer, shifting the oxygen-hemoglobin dissociation curve sharply to the left and impeding tissue oxygen offloading.
• Clinical Presentation: Asymptomatic slate-grey cyanosis refractory to supplemental oxygen, chocolate-brown arterial blood, and a pulse oximetry reading that plateaus stubbornly at ~85% (because methemoglobin exhibits equal light absorbance at both 660 nm and 940 nm wavelengths).
• Definitive Treatment: Administer Methylene Blue ($1 - 2\text{ mg/kg}$ IV over 5 minutes). Methylene blue acts as an electron acceptor/donor for the NADPH-methemoglobin reductase pathway, accelerating the enzymatic reduction of $MetHb$ back to functional hemoglobin. It is strictly contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (in whom methylene blue cannot be reduced to leukomethylene blue and may precipitate massive hemolytic anemia).

---

5. Local Anaesthetic Systemic Toxicity (LAST)

LAST is a potentially fatal adverse event resulting from excessive systemic plasma concentrations of local anaesthetic, triggered either by accidental direct intravascular injection or by rapid systemic absorption from vascular anatomical sites.

               [ SYSTEMIC ABSORPTION HIERARCHY: HIGHEST TO LOWEST ]
   Intravenous > Tracheal > Intercostal > Caudal > Paracervical > Epidural >
   Brachial Plexus > Femoral / Sciatic > Subcutaneous Infiltration
   (Mnemonic: 'In Time I Can Pull Every Boy Fooled Soon')

                     [ CELLULAR PATHOPHYSIOLOGY OF LAST ]
                                       |
        +------------------------------+------------------------------+
        |                                                             |
[ CENTRAL NERVOUS SYSTEM ]                                    [ CARDIOVASCULAR SYSTEM ]
Local anaesthetics cross blood-brain barrier                  Direct Myocardial Infiltration
        |                                                             |
Selectively Depress Inhibitory Cortical Neurons               1. Blocks Cardiac Sodium Channels (NaV1.5)
(GABAergic Interneurons in Amygdala & Cortex)                    - Bupivacaine: 'Fast In, Slow Out' kinetics
        |                                                        - Prolongs QRS, PR, QTc intervals
Unopposed Excitatory NMDA Signaling                              - Re-entrant VT, Torsades, VF
        |                                                             |
[ CNS EXCITATION ]                                            2. Inhibits Mitochondrial Energy Metabolism
Tinnitus, Metallic Taste, Lightheadedness,                       - Blocks Carnitine Palmitoyltransferase-1
Muscle Twitching, Generalized Tonic-Clonic Seizures              - Uncouples Oxidative Phosphorylation
        |                                                             |
Progressive Depressive Phase:                                 3. Depresses Myocardial Contractility
Coma, Apnea, Respiratory Arrest                               - Inhibits Intracellular Ca2+ Signaling
                                                              - Severe Negative Inotropy & Asystole

The Bupivacaine Cardiotoxicity Mechanism: "Fast In, Slow Out"

While lidocaine and bupivacaine both bind to cardiac sodium channels ($Na_V1.5$), their dissociation kinetics differ radically:

• Lidocaine ("Fast In, Fast Out"): Associates with the channel during Phase 0 systole and dissociates rapidly during Phase 4 diastole (recovery time constant about $0.15\text{ seconds}$). At physiological heart rates (60 to 80 bpm; diastolic interval ~0.6 seconds), lidocaine completely unbinds before the next action potential arrives.
• Bupivacaine ("Fast In, Slow Out"): Associates rapidly during systole but dissociates about ten times more slowly during diastole (recovery time constant about $1.5\text{ seconds}$). Diastolic intervals are insufficient to allow channel clearance. Consequently, with each successive heartbeat, bupivacaine progressively accumulates in cardiac sodium channels, causing profound, cumulative conduction slowing, marked QRS widening, complete AV block, refractory re-entrant ventricular tachycardias, and electromechanical dissociation.
• Cardiovascular Collapse to CNS Toxicity Ratio ($\text{CC/CNS}$ Ratio): The ratio of the dose required to produce irreversible cardiovascular collapse compared to that which provokes generalized seizures is $2.0$ for bupivacaine, compared to $7.0$ for lidocaine. Cardiotoxicity occurs almost simultaneously with CNS toxicity for bupivacaine.
• Stereoisomer Safety Margin: Commercial bupivacaine is a 50:50 racemic mixture of $R(+)$ and $S(-)$ enantiomers. The $R(+)$-isomer binds the cardiac sodium channel pore with dramatically higher affinity and dissociates more slowly than the $S(-)$-isomer. Levobupivacaine (the pure $S(-)$-enantiomer of bupivacaine) and ropivacaine (a pure $S(-)$-propyl homolog) possess significantly wider therapeutic safety margins, exhibiting higher CC/CNS ratios and reduced cardiotoxic potential.

Physiological Factors Aggravating LAST

• Acidosis and Hypercapnia: Acidemia decreases plasma protein binding to alpha-1-acid glycoprotein, doubling the concentration of free, biologically active local anaesthetic. Hypercapnia increases cerebral blood flow, accelerating drug delivery to the brain. Intracellular acidosis promotes intracellular ion trapping of the charged cation ($\text{BH}^+$) inside cardiac myocytes, exacerbating channel blockade.
• Hypoxemia and Hyperkalemia: Synergistically amplify conduction slowing and depress myocardial contractility.

---

6. Management of LAST: ASRA and Association of Anaesthetists Guidance

When Local Anaesthetic Systemic Toxicity is suspected, immediate, coordinated resuscitation must be initiated according to international guidance (the American Society of Regional Anesthesia and Pain Medicine 2020 checklist and the Association of Anaesthetists of Great Britain and Ireland LAST guideline).

                      [ IMMEDIATE LAST RESUSCITATION ALGORITHM ]
                                         |
           +-----------------------------+-----------------------------+
           |                                                           |
[ 1. STOP LA INJECTION ]                                    [ 2. CALL FOR HELP & LAST RESCUE KIT ]
Immediate cessation of drug                                 Summon Resuscitation Team
Secure Airway & 100% O2                                     Retrieve 20% Lipid Emulsion (Intralipid)
Hyperventilate mildly to prevent acidosis                   Alert ECMO / Perfusion Team Early
           |                                                           |
           +-----------------------------+-----------------------------+
                                         |
                                         v
[ 3. SUPPRESS SEIZURES & PREVENT HYPERCAPNIA ]
- Benzodiazepines (Midazolam 1-2 mg IV) are first-line
- Avoid propofol in hemodynamically unstable patients (potentiates cardiac depression)
- Neuromuscular blocker (Succinylcholine) to halt muscular acidosis if seizures persist
                                         |
                                         v
[ 4. RESUSCITATION MODIFICATIONS (CRUCIAL ACLS CHANGES) ]
- REDUCE Individual Epinephrine Boluses to <1 mcg/kg (e.g., 10-50 mcg boluses in adults)
  (Large 1-mg doses impair resuscitation, worsen acidosis, and reduce lipid rescue efficacy)
- AVOID Vasopressin (provokes adverse pulmonary and cardiac vasoconstriction)
- AVOID Calcium Channel Blockers and Beta-Blockers (aggravate myocardial depression)
- AVOID Class I Antiarrhythmics (Lidocaine, Procainamide) -> Fatal Sodium Channel Toxicity!
                                         |
                                         v
[ 5. DEFINITIVE 20% LIPID EMULSION THERAPY (INTRALIPID) ]
- BOLUS: 1.5 mL/kg IV over 1 minute (~100 mL in a 70-kg adult)
- INFUSION: 0.25 mL/kg/min immediately (~18 mL/min; ~1000 mL/h)
- If cardiovascular instability persists:
  * Repeat bolus of 1.5 mL/kg once or twice (every 3-5 minutes)
  * Double the infusion rate to 0.5 mL/kg/min
- Continue infusion for at least 15 minutes after hemodynamic stability is achieved
- MAXIMUM Recommended Dose: 12 mL/kg within the first hour

Mechanisms of Lipid Rescue Therapy

1. Lipid Sink / Metabolic Shuttle: 20% lipid emulsion creates an expanded intravascular lipid compartment. Lipophilic local anaesthetic molecules are partitioned out of aqueous plasma into the lipid emulsion droplets, establishing a concentration gradient that draws toxic drug molecules away from myocardial and cerebral tissues.
2. Direct Metabolic Inotropy: High-dose fatty acid infusion overcomes local anaesthetic-induced inhibition of mitochondrial carnitine palmitoyltransferase-1 (CPT-1), restoring substrate for beta-oxidation and ATP generation in the stunned myocardium.
3. Direct Membrane Ion Channel Effects: Free fatty acids promote opening of voltage-gated calcium channels, exerting an immediate positive inotropic effect and countering sodium channel block.
4. Cardiopulmonary Bypass / ECMO: If hemodynamic recovery does not occur following lipid emulsion and modified ACLS, venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides bridge support while the liver and tissues metabolize the bound local anaesthetic.